Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Retinitis Pigmentosa
Biotech
ProQR, Théa ink new pact for eye assets after old one collapsed
After an earlier version of the deal crumbled, ProQR has finally managed to sell off its ophthalmology assets to Laboratoires Théa.
Gabrielle Masson
Dec 8, 2023 11:01am
Nanoscope's gene therapy boosts vision function in phase 2 test
Mar 30, 2023 11:04am
J&J links gene therapy to improved vision in early-phase trial
Oct 3, 2022 8:00am
Drug for alcoholics might be the key to vision treatment
Mar 18, 2022 2:08pm
Second Sight slashes support for 'bionic eyes': report
Feb 17, 2022 11:48am
Biogen joins Harvard in gene therapy pact to fight eye disease
Jul 6, 2020 10:55am
